# Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

> **NCT00938223** · PHASE2 · COMPLETED · sponsor: **Craig L Slingluff, Jr** · enrollment: 51 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** 4-peptide and 12-peptide melanoma vaccines

## Key facts

- **NCT ID:** NCT00938223
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2003-11
- **Final completion:** —
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2018-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00938223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00938223, "Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00938223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*